The Experts below are selected from a list of 6054 Experts worldwide ranked by ideXlab platform

Eeva Leinonen - One of the best experts on this subject based on the ideXlab platform.

  • Neuroleptic Malignant Syndrome during olanzapine and levomepromazine treatment
    Acta Psychiatrica Scandinavica, 2000
    Co-Authors: K Jarventausta, Eeva Leinonen
    Abstract:

    Objective: To date only five reports of Neuroleptic Malignant Syndrome (NMS) related to olanzapine exist. The first case report was published in November 1998. Method: We report the case of a 78-year-old woman suffering from chronic schizophrenia who developed a NMS while being treated with olanzapine and levomepromazine. Before this her medication had been unchanged for more than 2 years. Results: When treated with olanzapine and levomepromazine, the patient had a fulminant NMS which was complicated with pneumonia. When the Neuroleptic drug treatment was discontinued, the patient recovered. However, when this combination was restarted later due to severe agitation and hallucinations, the symptoms of NMS reappeared. Conclusion: This case report shows that the Neuroleptic Malignant Syndrome can occur during olanzapine treatment as well as during treatment with conventional Neuroleptics. This Syndrome may develop even after a long and stable Neuroleptic treatment.

José A. Riancho - One of the best experts on this subject based on the ideXlab platform.

  • Neuroleptic Malignant Syndrome in the acquired immunodeficiency Syndrome.
    Postgraduate Medical Journal, 1997
    Co-Authors: José L. Hernández, L. Palacios-araus, S. Echevarría, A. Herrán, J. F. Campo, José A. Riancho
    Abstract:

    Patients infected by the human immunodeficiency virus are predisposed to many infectious and noninfectious complications and often receive a variety of drugs. Furthermore, they seem to have a particular susceptibility to idiosyncratic adverse drug reactions. It is therefore surprising that only a few cases of the Neuroleptic Malignant Syndrome have been described in patients with the acquired immunodeficiency Syndrome. A high index of suspicion is required to diagnose the Neuroleptic Malignant Syndrome in these patients, as its usual manifestations, including fever and altered consciousness, are frequently attributed to an underlying infection.

K Jarventausta - One of the best experts on this subject based on the ideXlab platform.

  • Neuroleptic Malignant Syndrome during olanzapine and levomepromazine treatment
    Acta Psychiatrica Scandinavica, 2000
    Co-Authors: K Jarventausta, Eeva Leinonen
    Abstract:

    Objective: To date only five reports of Neuroleptic Malignant Syndrome (NMS) related to olanzapine exist. The first case report was published in November 1998. Method: We report the case of a 78-year-old woman suffering from chronic schizophrenia who developed a NMS while being treated with olanzapine and levomepromazine. Before this her medication had been unchanged for more than 2 years. Results: When treated with olanzapine and levomepromazine, the patient had a fulminant NMS which was complicated with pneumonia. When the Neuroleptic drug treatment was discontinued, the patient recovered. However, when this combination was restarted later due to severe agitation and hallucinations, the symptoms of NMS reappeared. Conclusion: This case report shows that the Neuroleptic Malignant Syndrome can occur during olanzapine treatment as well as during treatment with conventional Neuroleptics. This Syndrome may develop even after a long and stable Neuroleptic treatment.

Dusan Hadzi-pavlovic - One of the best experts on this subject based on the ideXlab platform.

  • Case-Control Study of Neuroleptic Malignant Syndrome
    American Journal of Psychiatry, 1997
    Co-Authors: Perminder S. Sachdev, Catherine Mason, Dusan Hadzi-pavlovic
    Abstract:

    Objective: The authors performed a case-control study of Neuroleptic Malignant Syndrome to identify potential risk factors. Method: Twenty-five patients with Neuroleptic Malignant Syndrome were matched with 50 comparison subjects on age, sex, primary psychiatric diagnosis, and time of admission to the hospital. The records of all subjects were reviewed independently by two researchers for information on postulated risk factors. Exploratory direct comparisons of the two groups were followed by a conditional logistic regression analysis. Results: Patients with Neuroleptic Malignant Syndrome were more likely to be agitated or dehydrated before the development of Neuroleptic Malignant Syndrome, often needed restraint or seclusion, and received larger doses of Neuroleptics soon after hospitalization. Previous treatment with ECT increased vulnerability. Conclusions: The prevalence of Neuroleptic Malignant Syndrome may be reduced by avoiding large doses of Neuroleptics over short periods in the management of acute psychosis and by paying adequate attention to the patient’s hydration and electrolyte status. (Am J Psychiatry 1997; 154:1156‐1158)

Roland Veltkamp - One of the best experts on this subject based on the ideXlab platform.

  • Endovascular cooling in a patient with Neuroleptic Malignant Syndrome.
    Journal of the Neurological Sciences, 2008
    Co-Authors: Jennifer Diedler, Patricio Mellado, Roland Veltkamp
    Abstract:

    We report a case of severe Neuroleptic Malignant Syndrome with hyperthermia, rhabdomyolysis and hepatic failure where we applied endovascular cooling in order to reverse hyperthermia. After rapid normalization of core temperature at 37.5 degrees C, the patient's condition improved and CK levels dropped. However, upon withdrawl of endovascular temperature control there was a relapse. This is the first case where endovascular cooling was applied successfully in Neuroleptic Malignant Syndrome.

  • Endovascular cooling in a patient with Neuroleptic Malignant Syndrome
    Journal of the Neurological Sciences, 2007
    Co-Authors: Jennifer Diedler, Patricio Mellado, Roland Veltkamp
    Abstract:

    We report a case of severe Neuroleptic Malignant Syndrome with hyperthermia, rhabdomyolysis and hepatic failure where we applied endovascular cooling in order to reverse hyperthermia. After rapid normalization of core temperature at 37.5 °C, the patient's condition improved and CK levels dropped. However, upon withdrawl of endovascular temperature control there was a relapse. This is the first case where endovascular cooling was applied successfully in Neuroleptic Malignant Syndrome.